ADMA Biologics, Inc. (ADMA)

US — Healthcare Sector
Peers: ACAD  PRAX  BLTE  LGND  SLNO  MIRM  DYN  CRNX  TLX  RARE 

Automate Your Wheel Strategy on ADMA

With Tiblio's Option Bot, you can configure your own wheel strategy including ADMA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ADMA
  • Rev/Share 2.0476
  • Book/Share 1.8071
  • PB 9.6949
  • Debt/Equity 0.1928
  • CurrentRatio 7.1279
  • ROIC 0.3238

 

  • MktCap 4169720843.0
  • FreeCF/Share 0.1707
  • PFCF 102.3873
  • PE 19.9589
  • Debt/Assets 0.1462
  • DivYield 0
  • ROE 0.5398

 

  • Rating B+
  • Score 3
  • Recommendation Neutral
  • P/E Score 3
  • DCF Score 1
  • P/B Score 1
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

ADMA Biologics to Participate in the Raymond James Institutional Investor Conference
ADMA
Published: February 28, 2025 by: GlobeNewsWire
Sentiment: Neutral

RAMSEY, N.J. and BOCA RATON, Fla., Feb. 28, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the Raymond James Institutional Investor Conference on March 5, 2025, at 11:35 a.m. ET.

Read More
image for news ADMA Biologics to Participate in the Raymond James Institutional Investor Conference
ADMA Biologics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
ADMA
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral

RAMSEY, N.J. and BOCA RATON, Fla.

Read More
image for news ADMA Biologics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
Adma Biologics (ADMA) Stock Slides as Market Rises: Facts to Know Before You Trade
ADMA
Published: February 19, 2025 by: Zacks Investment Research
Sentiment: Negative

Adma Biologics (ADMA) closed the most recent trading day at $16.07, moving -0.62% from the previous trading session.

Read More
image for news Adma Biologics (ADMA) Stock Slides as Market Rises: Facts to Know Before You Trade
Pharma Stock Poised to Bounce Off Support
ADMA
Published: February 12, 2025 by: Schaeffers Research
Sentiment: Positive

Pharmaceutical concern ADMA Biologics Inc (NASDAQ:ADMA) has been consolidating above familiar pressure at the $16 region since mid-January.

Read More
image for news Pharma Stock Poised to Bounce Off Support

About ADMA Biologics, Inc. (ADMA)

  • IPO Date 2013-10-17
  • Website https://www.admabiologics.com
  • Industry Biotechnology
  • CEO Adam S. Grossman
  • Employees 685

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.